Company intelligence / Profile preview

Ivory Graft

Kefar Sava, Central District, Israelivorygraft.com ↗

Ownership: Private
Development stage: Commercial

Overview

Ivory Dentin Graft™ has demonstrated clinical superiority over traditional porcine cortico-cancellous bone grafts, showing higher rates of new bone formation and better integration with host bone. In a prospective randomized study, it achieved an average of ~60.75% new bone formation at four months post-procedure versus ~42.81% with comparator materials. The product is CE marked and commercially available in Europe; regulatory approval processes are ongoing elsewhere.

Therapeutic areas: OtherRheumatology
Modalities: Device (bone graft substitute)Biologic (xenograft-derived material)
Industry: Implantable Medical Devices

Partnerships

European commercial distribution partnersKey Opinion Leaders network being established across Europe

Beyond the preview

Go deeper on Ivory Graft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ivory Graft.

Explore the full profile